Clinical trial · Observational
Measuring Non-Enhancing Glioblastoma Progression
Quantifying Progression of Non-Enhancing Tumor in Patients With Recurrent Glioblastoma Treated With Antiangiogenic Agents
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical research study is to learn if magnetic resonance imaging with magnetic resonance spectroscopy ("MRI/MRS" scanning) can measure any extra growth in the tumor that does not show up on regular MRI images. This study procedure will be performed on patients with recurrent glioblastoma who are either being treated with chemotherapy that blocks blood vessel growth, or will soon begin this type of chemotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI/MRS Scan | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- MRI/MRS Scanning
- description
- Magnetic resonance imaging with magnetic resonance spectroscopy (MRI/MRS Scanning)
- interventionNames
- Procedure: MRI/MRS Scan
Primary outcomes (1)
- measure
- Functional MR Measurements
- timeFrame
- Baseline, Every 8 weeks and at Off Study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with histologically proven intracranial glioblastoma or gliosarcoma will be eligible for this protocol 2. Patients with recurrent glioblastoma or gliosarcoma who are scheduled to start systemic chemotherapy with bevacizumab. 3. Patients tumor must be located in an area that is amenable to the proposed imaging sequences. 4. Patients must be age 18 or older. 5. Karnofsky Performance Status Scale (KPS) \>/= 70. 6. Inclusion of Women and Minorities: Both men and women and members of all races and ethnic groups are eligible for this trial. 7. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policies of the hospital. The only acceptable consent form is the one attached at the end of this protocol. Exclusion Criteria: 1. Patients with histologically proven intracranial glioblastoma or gliosarcoma will be eligible for this protocol 2. Patients with recurrent glioblastoma or gliosarcoma who are scheduled to start systemic chemotherapy with bevacizumab. 3. Patients tumor must be located in an area that is amenable to the proposed imaging sequences. 4. Patients must be age 18 or older. 5. KPS \>/= 70. 6. Inclusion of Women and Minorities: Both men and women and members of all races and ethnic groups are eligible for this trial. 7. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policies of the hospital.
References
Publications (0)
Data not yet available